1.1
Lisocabtagene maraleucel (liso‑cel) is not recommended, within its marketing authorisation, for treating the following large B-cell lymphomas that are refractory to, or have relapsed within 12 months after, first-line chemoimmunotherapy in adults:
diffuse large B‑cell lymphoma
high-grade B‑cell lymphoma
primary mediastinal large B-cell lymphoma
follicular lymphoma grade 3B.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation